Baird Financial Group
VIVO

Baird Financial Group’s Meridian Bioscience Inc VIVO Stock Holding History

Baird Financial Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,781
Closed -$450K – 1877
2022
Q2 		$450K Sell
14,781
-44
-0.3% -$1.19K ﹤0.01% 1385
2022
Q1 		$385K Sell
14,825
-338
-2% -$8.04K ﹤0.01% 1520
2021
Q4 		$310K Sell
15,163
-5
-0% -$96 ﹤0.01% 1652
2021
Q3 		$292K Buy
+15,168
New +$302K ﹤0.01% 1679
2020
Q3 		– Sell
-118,173
Closed -$2.75M – 1595
2020
Q2 		$2.75M Buy
+118,173
New +$1.71M 0.01% 639

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baird Financial Group's VIVO Position: Q3 2022 in Review

Baird Financial Group sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 14,781 shares — an estimated $450K sold.

Baird Financial Group first reported a position in VIVO in Q2 2020 and held it in 5 quarters. The position peaked at $2.75M in Q2 2020. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • Baird Financial Group reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • Baird Financial Group sold 14,781 Meridian Bioscience Inc shares in Q3 2022, an estimated $450K.
  • Baird Financial Group first reported a position in Meridian Bioscience Inc in Q2 2020 and held it in 5 quarters.
  • Baird Financial Group's Meridian Bioscience Inc position peaked at $2.75M in Q2 2020.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Baird Financial Group's 13F filing for Q3 2022, filed 15 Nov 2022.